Updates on targeted therapies for acute myeloid leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Updates on targeted therapies for acute myeloid leukaemia

Published:2021-08-04 Issue:2 Volume:196 Page:316-328
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kayser Sabine¹²^ORCID,Levis Mark J.³^ORCID

Affiliation:

1. Medical Clinic and Policlinic I Hematology and Cellular Therapy University Hospital Leipzig Leipzig Germany

2. NCT Trial Center National Center of Tumor Diseases German Cancer Research Center (DKFZ) Heidelberg Germany

3. Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore MD USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17746

Reference82 articles.

1. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

2. Acute promyelocytic leukemia: where did we start, where are we now, and the future

3. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

4. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

2. Design, synthesis, and biological activity evaluation of novel HDAC3 selective inhibitors for combination with Venetoclax against acute myeloid leukemia;European Journal of Medicinal Chemistry;2024-10

3. Shikonin, a natural naphthoquinone phytochemical, exerts anti-leukemia effects in human CBF-AML cell lines and zebrafish xenograft models;Biomedicine & Pharmacotherapy;2024-10

4. Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations;Journal of Medicinal Chemistry;2024-09-11

5. Immune‐dysregulation harnessing in myeloid neoplasms;Cancer Medicine;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3